Proactive pharmacogenomics in azathioprine-treated pediatric inflammatory bowel disease at a Chinese tertiary hospital DOI Creative Commons
Cassandra Long, Ying Huang

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 26, 2025

Background Despite the emergence of numerous innovative targeted therapies for management pediatric inflammatory bowel disease (IBD), azathioprine continues to be a pivotal first-line therapeutic agent. Nonetheless, considerable frequency myelosuppression associated with its use warrants careful consideration and further investigation. This study aims investigate application pharmacogenomics in Chinese IBD treated azathioprine, elucidate association occurrence myelosuppression. Methods We conducted retrospective analysis determine prevalence pharmacogenetic abnormalities thiopurine-induced patients IBD. Results Among 227 underwent testing, abnormal genetypes occurred 66 patients, among which 7 exhibited aberrant TPMT 59 had NUDT15 . Of 58 who were 23 cases experienced All three children heterozygous mutations developed leukopenia following treatment. normal results, 20 (36.4%) myelosuppression, while 35 (63.6%) did not. The dose was below recommended level guidelines. mean (mg/kg/day) group 1.22 ± 0.32, compared 1.42 0.42 non-myelosuppression group, represented statistically significant difference (p < 0.05). Age, gender, concomitant biologics, mesalazine, or glucocorticoids not show differences between groups > Conclusion C415T is prevalent China an increased risk azathioprine-induced A reduced should considered IBD, even those profiles.

Language: Английский

DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system DOI Creative Commons
Xia Zhang, Yuyu Liu,

Qinming Hou

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 14, 2025

Introduction DNA methylation inhibitors have been approved for the prevention of Acute Myeloid Leukemia (AML), and their safety profile is not fully characterized. This study was aimed at evaluating adverse drug reactions (ADRs) by analyzing individual case reports (ICSRs) collected in EudraVigilance (EV) database. Materials methods The EV database managed European Medicines Agency adopted. standardized medical terminology set MedDRA utilized. ICSRs data treatment acute myeloid leukemia originated from (2005–2024). A descriptive exploration combined undertaken to assess age, gender patients, severity outcome ADR, event year, geographical origin qualification reporting source. comprehensive assessment made severe ADR cases. By means Reporting Odds Ratio (ROR) 95% Confidence Interval (CI), a non-proportional analysis ® SOC inhibitors. Statistical executed with SPSS version 23.0, p < 0.05 regarded as statistically significant. Result reveals that related AZACITIDINE increased 2005 2023, slight decline 2024, while those DECITABINE on rise since 2007. were associated majority males individuals aged 65–85. Healthcare professionals frequently reported significant portion these serious completely resolved. most common ADRs identified, certain had higher probability (e.g., Febrile neutropenia, Anamia, etc.) others Myelosuppression, Thrombocytopenia, etc.). Conclusion regarding consistent literature information disclosed. each high being reported. Although has advantage using database, it limited spontaneous system. Future improvements are needed accurately evaluate drugs.

Language: Английский

Citations

0
Exploring the Potential of Medicinal Plants in Bone Marrow Regeneration and Hematopoietic Stem Cell Therapy DOI Creative Commons
Okechukwu Paul-Chima Ugwu,

Ugo Alum Esther

International journal of bone marrow research., Journal Year: 2025, Volume and Issue: 8(1), P. 001 - 005

Published: Jan. 31, 2025

Blood cell production through hematopoiesis within the bone marrow serves both to maintain blood equilibrium and respond tissue injury infectious demands. Hematopoietic stem (HSC) therapy developments have revolutionized medical treatment approaches for anemia leukemia failure caused by chemotherapy or radiation exposure. The therapeutic compounds present in medicinal plants traditionally supported health researchers now understand these could help regenerate tissue. analysis investigates how phytochemicals affect HSC proliferation differentiation while supporting survival. Panax ginseng, Astragalus membranaceus, Curcuma longa receive special attention their documented ability enhance preclinical clinical settings. This review examines challenges that include standardization issues, toxicity concerns, regulatory barriers alongside future perspectives about combining plant-based therapies with traditional treatments improve recovery results.

Language: Английский

Citations

0
Proactive pharmacogenomics in azathioprine-treated pediatric inflammatory bowel disease at a Chinese tertiary hospital DOI Creative Commons
Cassandra Long, Ying Huang

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 26, 2025

Background Despite the emergence of numerous innovative targeted therapies for management pediatric inflammatory bowel disease (IBD), azathioprine continues to be a pivotal first-line therapeutic agent. Nonetheless, considerable frequency myelosuppression associated with its use warrants careful consideration and further investigation. This study aims investigate application pharmacogenomics in Chinese IBD treated azathioprine, elucidate association occurrence myelosuppression. Methods We conducted retrospective analysis determine prevalence pharmacogenetic abnormalities thiopurine-induced patients IBD. Results Among 227 underwent testing, abnormal genetypes occurred 66 patients, among which 7 exhibited aberrant TPMT 59 had NUDT15 . Of 58 who were 23 cases experienced All three children heterozygous mutations developed leukopenia following treatment. normal results, 20 (36.4%) myelosuppression, while 35 (63.6%) did not. The dose was below recommended level guidelines. mean (mg/kg/day) group 1.22 ± 0.32, compared 1.42 0.42 non-myelosuppression group, represented statistically significant difference (p < 0.05). Age, gender, concomitant biologics, mesalazine, or glucocorticoids not show differences between groups > Conclusion C415T is prevalent China an increased risk azathioprine-induced A reduced should considered IBD, even those profiles.

Language: Английский

Citations

0